THE NEXT
EVOLUTION IN
CELLULAR
MEDICINE
Celularity is fundamentally altering how we approach the treatment of Cancer, Infectious Diseases, and Degenerative Diseases through continuous, innovative application of new discoveries in cellular medicine.
BEST IN CLASS & SCALABLE
Cellular Medicine manufacturing
Featuring industry leading and diverse product lines
ALLOGENEIC PLATFORM
Built on two decades of science
Driven by a deep, seasoned management team
INNOVATIVE PLACENTA-DERIVED
T cells, NK Cells, and pluripotent stem cells
With greater expandability, persistence, and stem-ness
OUR MISSION
is to lead the next evolution in cellular medicine by delivering off-the-shelf allogeneic cellular therapies, at unparalleled scale, quality, and economics
OUR VISION
Harness the Unique Biology & Ready Availability of the Placenta
- Unmet Global NeedSignificant unmet global need for allogeneic cellular medicines delivered on-demand, off-the-shelf
- Groundbreaking ResearchGroundbreaking basic & translational research into the unique biological activity of placental-derived cells
- Pioneering TechnologyPioneering technology platform of placental-derived cellular medicines and advanced biomaterials
- Industry TimingThe time has arrived for cellular medicines that overcome barriers of scale, quality, and economics
Cellular Medicine Manufacturing
The Process is the Product
A fully integrated, purpose-built manufacturing, translational research and biobanking center
- Purpose built facility staffed by over 100 highly specialized scientists, engineers & technicians
- 150,000sq ft including laboratory and advanced manufacturing space for cellular medicine & biomaterials
- Clinical Scale – (9) Grade C/ISO 7 labs and (5) Grade D/ISO 8 labs ALL GMP-CAPABLE
The Latest From Our
NEWSROOM
Celularity Inc. expansion is driven by experienced Cellular Medicine leaders & innovators with deep expertise in clinical development & regulatory approval.
Celularity Announces Release of 100th Cord Blood Stem Cell Unit by its Lifebank Division
Joint Investor Conference Call
Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy
Celularity Announces Positive DMC Safety Review and Continuation of its Phase I/II CYNK-001-COVID-19 (CYNKCOVID) Study